{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:50:24Z","timestamp":1770753024967,"version":"3.50.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03029-0","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:35:15Z","timestamp":1757745315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-coding RNAs\u2019 pivotal importance in modulation of cancer sensitivity to Topotecan: a systematic review"],"prefix":"10.1007","volume":"42","author":[{"given":"Seyed Mostafa","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abouzar","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"3029_CR1","doi-asserted-by":"publisher","unstructured":"The Lancet Public, H. (2024). Inequalities in cancer: a major public health concern. Lancet Public Health, 9(3), e147. https:\/\/doi.org\/10.1016\/s2468-2667(24)00029-x","DOI":"10.1016\/s2468-2667(24)00029-x"},{"issue":"3","key":"3029_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3029_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcrpr.2017.07.001","volume":"4","author":"SH Hassanpour","year":"2017","unstructured":"Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4(4):127\u20139. https:\/\/doi.org\/10.1016\/j.jcrpr.2017.07.001.","journal-title":"J Cancer Res Pract"},{"issue":"5","key":"3029_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.gendis.2020.09.002","volume":"8","author":"A Upadhyay","year":"2021","unstructured":"Upadhyay A. Cancer: an unknown territory; rethinking before going ahead. Genes Dis. 2021;8(5):655\u201361. https:\/\/doi.org\/10.1016\/j.gendis.2020.09.002.","journal-title":"Genes Dis"},{"key":"3029_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.06.007","volume":"95","author":"S Kansara","year":"2023","unstructured":"Kansara S, et al. The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer. Semin Cancer Biol. 2023;95:1\u201312. https:\/\/doi.org\/10.1016\/j.semcancer.2023.06.007.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"3029_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/s12276-024-01307-x","volume":"56","author":"SY Kim","year":"2024","unstructured":"Kim SY, et al. The roles and mechanisms of coding and noncoding RNA variations in cancer. Exp Mol Med. 2024;56(9):1909\u201320. https:\/\/doi.org\/10.1038\/s12276-024-01307-x.","journal-title":"Exp Mol Med"},{"issue":"1","key":"3029_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-023-02741-x","volume":"42","author":"M Ahmad","year":"2023","unstructured":"Ahmad M, et al. Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk. J Exp Clin Cancer Res. 2023;42(1):173. https:\/\/doi.org\/10.1186\/s13046-023-02741-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3029_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, et al. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188\u2013206. https:\/\/doi.org\/10.1038\/s41571-021-00585-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"3029_CR9","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.2147\/ijn.S200253","volume":"14","author":"G Mahmoodi Chalbatani","year":"2019","unstructured":"Mahmoodi Chalbatani G, et al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int J Nanomedicine. 2019;14:3111\u201328. https:\/\/doi.org\/10.2147\/ijn.S200253.","journal-title":"Int J Nanomedicine"},{"key":"3029_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.148066","volume":"897","author":"Z Xu","year":"2024","unstructured":"Xu Z, Nemati S. Long intergenic non-protein coding RNA 115 (Linc00115): a notable oncogene in human malignancies. Gene. 2024;897:148066. https:\/\/doi.org\/10.1016\/j.gene.2023.148066.","journal-title":"Gene"},{"issue":"1","key":"3029_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino MTD, Tagliaferri P, Tassone P. Microrna in cancer therapy: breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 2025;44(1):126. https:\/\/doi.org\/10.1186\/s13046-025-03391-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"3029_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, et al. Overview of microrna biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402. https:\/\/doi.org\/10.3389\/fendo.2018.00402.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"3029_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/cej.0000000000000645","volume":"30","author":"MA Mishan","year":"2021","unstructured":"Mishan MA, et al. Role of micrornas in the anticancer effects of the flavonoid luteolin: a systematic review. Eur J Cancer Prev. 2021;30(5):413\u201321. https:\/\/doi.org\/10.1097\/cej.0000000000000645.","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"3029_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.34172\/apb.2023.047","volume":"13","author":"B Shademan","year":"2023","unstructured":"Shademan B, et al. Micrornas as targets for cancer diagnosis: interests and limitations. Adv Pharm Bull. 2023;13(3):435\u201345. https:\/\/doi.org\/10.34172\/apb.2023.047.","journal-title":"Adv Pharm Bull"},{"key":"3029_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101613","volume":"28","author":"F Ghamlouche","year":"2023","unstructured":"Ghamlouche F, et al. Micrornas as clinical tools for diagnosis, prognosis, and therapy in prostate cancer. Transl Oncol. 2023;28:101613. https:\/\/doi.org\/10.1016\/j.tranon.2022.101613.","journal-title":"Transl Oncol"},{"key":"3029_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911502","author":"A Menon","year":"2022","unstructured":"Menon A, et al. miRNA: a promising therapeutic target in cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911502.","journal-title":"Int J Mol Sci"},{"key":"3029_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6830560","volume":"2021","author":"MA Khazeei Tabari","year":"2021","unstructured":"Khazeei Tabari MA, et al. Noncoding RNA roles in pharmacogenomic responses to aspirin: new molecular mechanisms for an old drug. BioMed Res Int. 2021;2021:6830560. https:\/\/doi.org\/10.1155\/2021\/6830560.","journal-title":"BioMed Res Int"},{"issue":"5","key":"3029_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2174\/1566524022666220405125900","volume":"23","author":"E Hasheminasabgorji","year":"2023","unstructured":"Hasheminasabgorji E, et al. MiR-638: a promising cancer biomarker with therapeutic potential. Curr Mol Med. 2023;23(5):377\u201389. https:\/\/doi.org\/10.2174\/1566524022666220405125900.","journal-title":"Curr Mol Med"},{"issue":"1","key":"3029_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188552","volume":"1876","author":"M Pandey","year":"2021","unstructured":"Pandey M, et al. Role of micrornas in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188552. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188552.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3029_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04078-y","author":"M Khandan","year":"2025","unstructured":"Khandan M, et al. The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic review. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04078-y.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"21","key":"3029_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3978\/j.issn.2305-5839.2015.11.32","volume":"3","author":"P Magee","year":"2015","unstructured":"Magee P, Shi L, Garofalo M. Role of microRNAs in chemoresistance. Ann Transl Med. 2015;3(21):332. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.11.32.","journal-title":"Ann Transl Med"},{"key":"3029_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041090","author":"L Pavl\u00edkov\u00e1","year":"2022","unstructured":"Pavl\u00edkov\u00e1 L, et al. The roles of microRNAs in cancer multidrug resistance. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14041090.","journal-title":"Cancers (Basel)"},{"key":"3029_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105846","author":"P Stasiak","year":"2022","unstructured":"Stasiak P, et al. The profile of microrna expression and potential role in the regulation of drug-resistant genes in doxorubicin and topotecan resistant ovarian cancer cell lines. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23105846.","journal-title":"Int J Mol Sci"},{"key":"3029_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fgene.2020.00775","volume":"11","author":"BK Sinha","year":"2020","unstructured":"Sinha BK, Tokar EJ, Bushel PR. Elucidation of mechanisms of Topotecan-induced cell death in human breast MCF-7 cancer cells by gene expression analysis. Front Genet. 2020;11:775. https:\/\/doi.org\/10.3389\/fgene.2020.00775.","journal-title":"Front Genet"},{"issue":"36","key":"3029_CR25","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/jco.21.00358","volume":"39","author":"PJ Leavey","year":"2021","unstructured":"Leavey PJ, et al. Phase III trial adding Vincristine-Topotecan-Cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: a Children\u2019s Oncology Group report. J Clin Oncol. 2021;39(36):4029\u201338. https:\/\/doi.org\/10.1200\/jco.21.00358.","journal-title":"J Clin Oncol"},{"issue":"21","key":"3029_CR26","doi-asserted-by":"publisher","first-page":"7935","DOI":"10.1002\/cam4.3422","volume":"9","author":"KA Jaeckle","year":"2020","unstructured":"Jaeckle KA, et al. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Med. 2020;9(21):7935\u201342. https:\/\/doi.org\/10.1002\/cam4.3422.","journal-title":"Cancer Med"},{"issue":"1","key":"3029_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1186\/s12885-019-6186-z","volume":"19","author":"P Rujkijyanont","year":"2019","unstructured":"Rujkijyanont P, et al. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study. BMC Cancer. 2019;19(1):961. https:\/\/doi.org\/10.1186\/s12885-019-6186-z.","journal-title":"BMC Cancer"},{"issue":"1","key":"3029_CR28","doi-asserted-by":"publisher","first-page":"19295","DOI":"10.1038\/s41598-023-44993-9","volume":"13","author":"MA De Ioris","year":"2023","unstructured":"De Ioris MA, et al. Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series. Sci Rep. 2023;13(1):19295. https:\/\/doi.org\/10.1038\/s41598-023-44993-9.","journal-title":"Sci Rep"},{"issue":"4","key":"3029_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ncrna.2021.12.001","volume":"6","author":"P Mondal","year":"2021","unstructured":"Mondal P, Meeran SM. Micrornas in cancer chemoresistance: the sword and the shield. Noncoding RNA Res. 2021;6(4):200\u201310. https:\/\/doi.org\/10.1016\/j.ncrna.2021.12.001.","journal-title":"Noncoding RNA Res"},{"key":"3029_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155742","volume":"265","author":"M Bagheri","year":"2025","unstructured":"Bagheri M, Akrami H. Studying the non-coding RNA expression and its role in drug resistance mechanisms of gastric cancer. Pathol Res Pract. 2025;265:155742. https:\/\/doi.org\/10.1016\/j.prp.2024.155742.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"3029_CR31","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.21873\/anticanres.11493","volume":"37","author":"A Klejewski","year":"2017","unstructured":"Klejewski A, et al. New and old genes associated with topotecan resistance development in ovarian cancer cell lines. Anticancer Res. 2017;37(4):1625\u201336. https:\/\/doi.org\/10.21873\/anticanres.11493.","journal-title":"Anticancer Res"},{"issue":"10","key":"3029_CR32","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1167\/iovs.09-3520","volume":"50","author":"CL Dalgard","year":"2009","unstructured":"Dalgard CL, et al. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci. 2009;50(10):4542\u201351. https:\/\/doi.org\/10.1167\/iovs.09-3520.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3029_CR33","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8100","author":"T Zeng","year":"2021","unstructured":"Zeng T, et al. Autophagy inhibition and microRNA-199a-5p upregulation in paclitaxel-resistant A549\/T lung cancer cells. Oncol Rep. 2021. https:\/\/doi.org\/10.3892\/or.2021.8100.","journal-title":"Oncol Rep"},{"key":"3029_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011020","author":"CY Lin","year":"2021","unstructured":"Lin CY, et al. Inhibition of BIRC2 sensitizes \u03b17-HPV-related cervical squamous cell carcinoma to chemotherapy. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222011020.","journal-title":"Int J Mol Sci"},{"key":"3029_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113378","author":"YM Rustum","year":"2018","unstructured":"Rustum YM, et al. Non-coding micro RNAs and hypoxia-inducible factors are selenium targets for development of a mechanism-based combination strategy in clear-cell renal cell carcinoma-bench-to-bedside therapy. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19113378.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"3029_CR36","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1021\/acs.jmedchem.7b01891","volume":"61","author":"Y Naro","year":"2018","unstructured":"Naro Y, et al. Small molecule inhibition of MicroRNA miR-21 rescues chemosensitivity of renal-cell carcinoma to topotecan. J Med Chem. 2018;61(14):5900\u20139. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01891.","journal-title":"J Med Chem"},{"key":"3029_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010049","author":"H Ho-Xuan","year":"2020","unstructured":"Ho-Xuan H, et al. Gene expression signatures of a preclinical mouse model during colorectal cancer progression under low-dose metronomic chemotherapy. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers13010049.","journal-title":"Cancers"},{"issue":"2","key":"3029_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.yexcr.2015.09.011","volume":"338","author":"KK To","year":"2015","unstructured":"To KK, Leung WW, Ng SS. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res. 2015;338(2):222\u201331. https:\/\/doi.org\/10.1016\/j.yexcr.2015.09.011.","journal-title":"Exp Cell Res"},{"issue":"1","key":"3029_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3727\/096504010x12828372551759","volume":"19","author":"A Misawa","year":"2010","unstructured":"Misawa A, et al. AP-1-dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol Res. 2010;19(1):23\u201333. https:\/\/doi.org\/10.3727\/096504010x12828372551759.","journal-title":"Oncol Res"},{"issue":"1","key":"3029_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3892\/or.2015.4331","volume":"35","author":"H Liao","year":"2016","unstructured":"Liao H, et al. Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK\/mTOR pathway in prostate cancer. Oncol Rep. 2016;35(1):64\u201372. https:\/\/doi.org\/10.3892\/or.2015.4331.","journal-title":"Oncol Rep"},{"issue":"2","key":"3029_CR41","first-page":"27","volume":"7","author":"TT Ho","year":"2016","unstructured":"Ho TT, et al. Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol. 2016;7(2):27\u201347.","journal-title":"Int J Biochem Mol Biol"},{"issue":"3","key":"3029_CR42","first-page":"390","volume":"6","author":"M Saaiq","year":"2017","unstructured":"Saaiq M, Ashraf B. Modifying \u201cPico\u201d question into \u201cPicos\u201d model for more robust and reproducible presentation of the methodology employed in a scientific study. World J Plast Surg. 2017;6(3):390\u20132.","journal-title":"World J Plast Surg"},{"key":"3029_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"BMJ"},{"key":"3029_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205124","author":"V Suresh Babu","year":"2022","unstructured":"Suresh Babu V, et al. Enhanced epithelial-to-mesenchymal transition and chemoresistance in advanced retinoblastoma tumors is driven by miR-181a. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14205124.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"3029_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/iovs.61.14.8","volume":"61","author":"D Saengwimol","year":"2020","unstructured":"Saengwimol D, et al. Silencing of the long noncoding RNA MYCNOS1 suppresses activity of MYCN-amplified retinoblastoma without RB1 mutation. Invest Ophthalmol Vis Sci. 2020;61(14):8. https:\/\/doi.org\/10.1167\/iovs.61.14.8.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3029_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/gutjnl-2011-301585","volume":"62","author":"C Hackl","year":"2013","unstructured":"Hackl C, et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 2013;62(2):259\u201371. https:\/\/doi.org\/10.1136\/gutjnl-2011-301585.","journal-title":"Gut"},{"issue":"1","key":"3029_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","volume":"17","author":"Z Wu","year":"2024","unstructured":"Wu Z, Xia F, Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: a systematic analysis for the GBD 2021. J Hematol Oncol. 2024;17(1):119. https:\/\/doi.org\/10.1186\/s13045-024-01640-8.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3029_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"issue":"1","key":"3029_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, et al. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1):109. https:\/\/doi.org\/10.1186\/s12964-023-01302-1.","journal-title":"Cell Commun Signal"},{"key":"3029_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117804","volume":"183","author":"M \u015awierczewska","year":"2025","unstructured":"\u015awierczewska M, et al. Doxorubicin and topotecan resistance in ovarian cancer: gene expression and microenvironment analysis in 2D and 3D models. Biomed Pharmacother. 2025;183:117804.","journal-title":"Biomed Pharmacother"},{"key":"3029_CR51","doi-asserted-by":"publisher","first-page":"1528230","DOI":"10.3389\/fimmu.2025.1528230","volume":"16","author":"P Jalali","year":"2025","unstructured":"Jalali P, et al. The role of autophagy in cancer: from molecular mechanism to therapeutic window. Front Immunol. 2025;16:1528230. https:\/\/doi.org\/10.3389\/fimmu.2025.1528230.","journal-title":"Front Immunol"},{"issue":"1","key":"3029_CR52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41419-025-07926-0","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, et al. The RNA-binding protein CELF1 targets ATG5 to regulate autophagy and promote drug resistance in acute myeloid leukemia. Cell Death Dis. 2025;16(1):599. https:\/\/doi.org\/10.1038\/s41419-025-07926-0.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3029_CR53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41418-019-0474-7","volume":"27","author":"JM Mulcahy Levy","year":"2020","unstructured":"Mulcahy Levy JM, Thorburn A. Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ. 2020;27(3):843\u201357. https:\/\/doi.org\/10.1038\/s41418-019-0474-7.","journal-title":"Cell Death Differ"},{"issue":"2","key":"3029_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cpr.12167","volume":"48","author":"T Xie","year":"2015","unstructured":"Xie T, et al. Untangling knots between autophagic targets and candidate drugs, in cancer therapy. Cell Prolif. 2015;48(2):119\u201339. https:\/\/doi.org\/10.1111\/cpr.12167.","journal-title":"Cell Prolif"},{"key":"3029_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejmech.2017.12.046","volume":"144","author":"Z Pan","year":"2018","unstructured":"Pan Z, et al. Design, synthesis, and biological evaluation of polo-like kinase 1\/eukaryotic elongation factor 2 kinase (PLK1\/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy. Eur J Med Chem. 2018;144:517\u201328. https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.046.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"3029_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12402","volume":"51","author":"D Sun","year":"2018","unstructured":"Sun D, et al. Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. Cell Prolif. 2018;51(2):e12402. https:\/\/doi.org\/10.1111\/cpr.12402.","journal-title":"Cell Prolif"},{"key":"3029_CR57","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3389\/fimmu.2018.02334","volume":"9","author":"X Ye","year":"2018","unstructured":"Ye X, Zhou XJ, Zhang H. Exploring the role of autophagy-related gene 5 (ATG5) yields important insights into autophagy in autoimmune\/autoinflammatory diseases. Front Immunol. 2018;9:2334. https:\/\/doi.org\/10.3389\/fimmu.2018.02334.","journal-title":"Front Immunol"},{"issue":"4","key":"3029_CR58","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1083\/jcb.200507002","volume":"171","author":"G Bj\u00f8rk\u00f8y","year":"2005","unstructured":"Bj\u00f8rk\u00f8y G, et al. p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005;171(4):603\u201314. https:\/\/doi.org\/10.1083\/jcb.200507002.","journal-title":"J Cell Biol"},{"issue":"5","key":"3029_CR59","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/cr.2017.40","volume":"27","author":"H Peng","year":"2017","unstructured":"Peng H, et al. Ubiquitylation of p62\/sequestosome1 activates its autophagy receptor function and controls selective autophagy upon ubiquitin stress. Cell Res. 2017;27(5):657\u201374. https:\/\/doi.org\/10.1038\/cr.2017.40.","journal-title":"Cell Res"},{"issue":"1","key":"3029_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12920-020-0661-x","volume":"13","author":"J Liang","year":"2020","unstructured":"Liang J, et al. Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer. BMC Med Genomics. 2020;13(1):7. https:\/\/doi.org\/10.1186\/s12920-020-0661-x.","journal-title":"BMC Med Genomics"},{"issue":"5","key":"3029_CR61","doi-asserted-by":"publisher","first-page":"591","DOI":"10.21873\/cgp.20344","volume":"19","author":"MK Lee","year":"2022","unstructured":"Lee MK, et al. Prognostic significance of the BIRC2-BIRC3 gene signature in head and neck squamous cell carcinoma. Cancer Genomics Proteomics. 2022;19(5):591\u2013605. https:\/\/doi.org\/10.21873\/cgp.20344.","journal-title":"Cancer Genomics Proteomics"},{"issue":"8","key":"3029_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108073","volume":"32","author":"D Samanta","year":"2020","unstructured":"Samanta D, et al. BIRC2 expression impairs anti-cancer immunity and immunotherapy efficacy. Cell Rep. 2020;32(8):108073. https:\/\/doi.org\/10.1016\/j.celrep.2020.108073.","journal-title":"Cell Rep"},{"issue":"6","key":"3029_CR63","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.ctrv.2012.01.005","volume":"38","author":"S Fulda","year":"2012","unstructured":"Fulda S. Inhibitor of apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treat Rev. 2012;38(6):760\u20136. https:\/\/doi.org\/10.1016\/j.ctrv.2012.01.005.","journal-title":"Cancer Treat Rev"},{"key":"3029_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050798","author":"A Yfantis","year":"2023","unstructured":"Yfantis A, et al. Transcriptional response to hypoxia: the role of HIF-1-associated co-regulators. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12050798.","journal-title":"Cells"},{"key":"3029_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041752","author":"M Jalouli","year":"2025","unstructured":"Jalouli M. Emerging role of hypoxia-inducible factors (HIFs) in modulating autophagy: perspectives on cancer therapy. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26041752.","journal-title":"Int J Mol Sci"},{"key":"3029_CR66","doi-asserted-by":"publisher","DOI":"10.1172\/jci159839","author":"EE Wicks","year":"2022","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci159839.","journal-title":"J Clin Invest"},{"key":"3029_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586.","journal-title":"Eur J Pharmacol"},{"key":"3029_CR68","first-page":"378","volume":"21","author":"A Bagheri","year":"2015","unstructured":"Bagheri A, et al. Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells. Mol Vis. 2015;21:378\u201390.","journal-title":"Mol Vis"},{"issue":"3","key":"3029_CR69","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"3029_CR70","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","volume":"23","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, et al. PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Mol Cancer. 2024;23(1):146. https:\/\/doi.org\/10.1186\/s12943-024-02059-y.","journal-title":"Mol Cancer"},{"issue":"4","key":"3029_CR71","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.eururo.2015.11.029","volume":"70","author":"Y Messai","year":"2016","unstructured":"Messai Y, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of Hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. 2016;70(4):623\u201332. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.029.","journal-title":"Eur Urol"},{"issue":"2","key":"3029_CR72","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.30077","volume":"139","author":"M Ruf","year":"2016","unstructured":"Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139(2):396\u2013403. https:\/\/doi.org\/10.1002\/ijc.30077.","journal-title":"Int J Cancer"},{"issue":"18","key":"3029_CR73","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1158\/0008-5472.Can-15-0405","volume":"75","author":"MZ Noman","year":"2015","unstructured":"Noman MZ, et al. Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res. 2015;75(18):3771\u201387. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0405.","journal-title":"Cancer Res"},{"key":"3029_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/boc.201800014","author":"Q Wang","year":"2018","unstructured":"Wang Q, Yang HS. The role of Pdcd4 in tumour suppression and protein translation. Biol Cell. 2018. https:\/\/doi.org\/10.1111\/boc.201800014.","journal-title":"Biol Cell"},{"key":"3029_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.855807","volume":"12","author":"Q Cai","year":"2022","unstructured":"Cai Q, et al. Dissecting the roles of PDCD4 in breast cancer. Front Oncol. 2022;12:855807. https:\/\/doi.org\/10.3389\/fonc.2022.855807.","journal-title":"Front Oncol"},{"key":"3029_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/genes11070719","author":"N Fusco","year":"2020","unstructured":"Fusco N, et al. PTEN alterations and their role in cancer management: are we making headway on precision medicine? Genes (Basel). 2020. https:\/\/doi.org\/10.3390\/genes11070719.","journal-title":"Genes (Basel)"},{"issue":"12","key":"3029_CR77","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/1947601911407325","volume":"1","author":"MM Georgescu","year":"2010","unstructured":"Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer. 2010;1(12):1170\u20137. https:\/\/doi.org\/10.1177\/1947601911407325.","journal-title":"Genes Cancer"},{"issue":"4","key":"3029_CR78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/10799893.2012.695798","volume":"32","author":"MA Chetram","year":"2012","unstructured":"Chetram MA, Hinton CV. Pten regulation of ERK1\/2 signaling in cancer. J Recept Signal Transduct Res. 2012;32(4):190\u20135. https:\/\/doi.org\/10.3109\/10799893.2012.695798.","journal-title":"J Recept Signal Transduct Res"},{"issue":"2","key":"3029_CR79","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3892\/ol.2019.10398","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, et al. Programmed cell death factor 4 enhances the chemosensitivity of colorectal cancer cells to taxol. Oncol Lett. 2019;18(2):1402\u20138. https:\/\/doi.org\/10.3892\/ol.2019.10398.","journal-title":"Oncol Lett"},{"issue":"1","key":"3029_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41420-025-02310-5","volume":"11","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, et al. The crosstalk between SND1 and PDCD4 is associated with chemoresistance of non-small cell lung carcinoma cells. Cell Death Discov. 2025;11(1):34. https:\/\/doi.org\/10.1038\/s41420-025-02310-5.","journal-title":"Cell Death Discov"},{"issue":"1","key":"3029_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13046-023-02823-w","volume":"42","author":"F Zheng","year":"2023","unstructured":"Zheng F, et al. PINK1-PTEN axis promotes metastasis and chemoresistance in ovarian cancer via non-canonical pathway. J Exp Clin Cancer Res. 2023;42(1):295. https:\/\/doi.org\/10.1186\/s13046-023-02823-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"3029_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147767","author":"G Antonio-Andres","year":"2024","unstructured":"Antonio-Andres G, et al. The role of PTEN in chemoresistance mediated by the HIF-1\u03b1\/YY1 axis in pediatric acute lymphoblastic leukemia. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25147767.","journal-title":"Int J Mol Sci"},{"key":"3029_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2022.102527","volume":"102","author":"SH Gao","year":"2022","unstructured":"Gao SH, et al. Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer. Cell Calcium. 2022;102:102527. https:\/\/doi.org\/10.1016\/j.ceca.2022.102527.","journal-title":"Cell Calcium"},{"issue":"7","key":"3029_CR84","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41419-022-05099-8","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, et al. ARHGEF2\/EDN1 pathway participates in ER stress-related drug resistance of hepatocellular carcinoma by promoting angiogenesis and malignant proliferation. Cell Death Dis. 2022;13(7):652. https:\/\/doi.org\/10.1038\/s41419-022-05099-8.","journal-title":"Cell Death Dis"},{"key":"3029_CR85","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2019.02.040","volume":"450","author":"Z Fan","year":"2019","unstructured":"Fan Z, et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt\/\u03b2-catenin signaling. Cancer Lett. 2019;450:132\u201343. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.040.","journal-title":"Cancer Lett"},{"issue":"11","key":"3029_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32676","volume":"10","author":"X Zhou","year":"2024","unstructured":"Zhou X, et al. SIAH1 facilitates the migration and invasion of gastric cancer cells through promoting the ubiquitination and degradation of RECK. Heliyon. 2024;10(11):e32676. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32676.","journal-title":"Heliyon"},{"issue":"3","key":"3029_CR87","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12253-009-9226-1","volume":"16","author":"F Guo","year":"2010","unstructured":"Guo F, et al. Identification of Rho GTPase activating protein 6 isoform 1 variant as a new molecular marker in human colorectal tumors. Pathol Oncol Res. 2010;16(3):319\u201326. https:\/\/doi.org\/10.1007\/s12253-009-9226-1.","journal-title":"Pathol Oncol Res"},{"key":"3029_CR88","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2876848\/v1","author":"Z Fang","year":"2023","unstructured":"Fang Z, et al. NME4 promotes cell malignant process by targeting SMAD2 in colorectal cancer. Res Square. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-2876848\/v1.","journal-title":"Res Square"},{"issue":"4","key":"3029_CR89","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/15384101.2015.1006048","volume":"14","author":"P Zhang","year":"2015","unstructured":"Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14(4):481\u20137. https:\/\/doi.org\/10.1080\/15384101.2015.1006048.","journal-title":"Cell Cycle"},{"issue":"7","key":"3029_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040378","volume":"7","author":"N Fenouille","year":"2012","unstructured":"Fenouille N, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS ONE. 2012;7(7):e40378. https:\/\/doi.org\/10.1371\/journal.pone.0040378.","journal-title":"PLoS ONE"},{"issue":"8","key":"3029_CR91","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/emmm.201302827","volume":"5","author":"FA Siebzehnrubl","year":"2013","unstructured":"Siebzehnrubl FA, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med. 2013;5(8):1196\u2013212. https:\/\/doi.org\/10.1002\/emmm.201302827.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"3029_CR92","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41419-017-0087-3","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, et al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis. 2018;9(2):57. https:\/\/doi.org\/10.1038\/s41419-017-0087-3.","journal-title":"Cell Death Dis"},{"key":"3029_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092701","author":"K Wieczorek-Szukala","year":"2020","unstructured":"Wieczorek-Szukala K, et al. Snail-1 overexpression correlates with metastatic phenotype in BRAF(V600E) positive papillary thyroid carcinoma. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9092701.","journal-title":"J Clin Med"},{"issue":"7","key":"3029_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119528","volume":"1870","author":"S Shivhare","year":"2023","unstructured":"Shivhare S, et al. ZEB1 potentiates chemoresistance in breast cancer stem cells by evading apoptosis. Biochim Biophys Acta Mol Cell Res. 2023;1870(7):119528. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119528.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"6","key":"3029_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189003","volume":"1878","author":"M Kielbik","year":"2023","unstructured":"Kielbik M, et al. Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189003. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189003.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"3029_CR96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4149\/neo_2016_004","volume":"63","author":"G Qin","year":"2016","unstructured":"Qin G, et al. Cathepsin l is involved in proliferation and invasion of breast cancer cells. Neoplasma. 2016;63(1):30\u20136. https:\/\/doi.org\/10.4149\/neo_2016_004.","journal-title":"Neoplasma"},{"key":"3029_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran TB, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652. https:\/\/doi.org\/10.3389\/fonc.2022.891652.","journal-title":"Front Oncol"},{"issue":"9","key":"3029_CR98","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/cdd.2011.30","volume":"18","author":"M Olsson","year":"2011","unstructured":"Olsson M, Zhivotovsky B. Caspases and cancer. Cell Death Differ. 2011;18(9):1441\u20139. https:\/\/doi.org\/10.1038\/cdd.2011.30.","journal-title":"Cell Death Differ"},{"issue":"6","key":"3029_CR99","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s12276-025-01470-9","volume":"57","author":"SH Dho","year":"2025","unstructured":"Dho SH, et al. Caspases as master regulators of programmed cell death: apoptosis, pyroptosis and beyond. Exp Mol Med. 2025;57(6):1121\u201332. https:\/\/doi.org\/10.1038\/s12276-025-01470-9.","journal-title":"Exp Mol Med"},{"issue":"1","key":"3029_CR100","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biocel.2009.09.013","volume":"42","author":"M Lamkanfi","year":"2010","unstructured":"Lamkanfi M, Kanneganti TD. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 2010;42(1):21\u20134. https:\/\/doi.org\/10.1016\/j.biocel.2009.09.013.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5762","key":"3029_CR101","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.1115035","volume":"311","author":"SA Lakhani","year":"2006","unstructured":"Lakhani SA, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 2006;311(5762):847\u201351. https:\/\/doi.org\/10.1126\/science.1115035.","journal-title":"Science"},{"key":"3029_CR102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/btt.S436629","volume":"18","author":"W Lin","year":"2024","unstructured":"Lin W, et al. MDMX in cancer: a partner of p53 and a p53-independent effector. Biologics. 2024;18:61\u201378. https:\/\/doi.org\/10.2147\/btt.S436629.","journal-title":"Biologics"},{"issue":"11","key":"3029_CR103","first-page":"5233","volume":"11","author":"NA Yousafzai","year":"2021","unstructured":"Yousafzai NA, et al. Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer. Am J Cancer Res. 2021;11(11):5233\u201348.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"3029_CR104","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1084\/jem.20150308","volume":"212","author":"N Mende","year":"2015","unstructured":"Mende N, et al. CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo. J Exp Med. 2015;212(8):1171\u201383. https:\/\/doi.org\/10.1084\/jem.20150308.","journal-title":"J Exp Med"},{"key":"3029_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911892","author":"Y Deng","year":"2022","unstructured":"Deng Y, et al. Identification of candidate genes in breast cancer induced by estrogen plus progestogens using bioinformatic analysis. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911892.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3029_CR106","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/0092-8674(95)90034-9","volume":"82","author":"P Sicinski","year":"1995","unstructured":"Sicinski P, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995;82(4):621\u201330. https:\/\/doi.org\/10.1016\/0092-8674(95)90034-9.","journal-title":"Cell"},{"issue":"8","key":"3029_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166816","volume":"1869","author":"L Wei","year":"2023","unstructured":"Wei L, et al. E2f3 induces DNA damage repair, stem-like properties and therapy resistance in breast cancer. Biochim Biophys Acta Mol Basis Dis. 2023;1869(8):166816. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166816.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"21\u201322","key":"3029_CR108","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/17520363.2024.2416887","volume":"18","author":"Y Xie","year":"2024","unstructured":"Xie Y, et al. Epithelial membrane protein 1 in human cancer: a potential diagnostic biomarker and therapeutic target. Biomark Med. 2024;18(21\u201322):995\u20131005. https:\/\/doi.org\/10.1080\/17520363.2024.2416887.","journal-title":"Biomark Med"},{"key":"3029_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cells11081330","author":"NY Park","year":"2022","unstructured":"Park NY, Jo DS, Cho DH. Post-translational modifications of ATG4B in the regulation of autophagy. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11081330.","journal-title":"Cells"},{"issue":"10","key":"3029_CR110","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/15548627.2019.1709763","volume":"16","author":"X Zheng","year":"2020","unstructured":"Zheng X, et al. The protease activity of human ATG4B is regulated by reversible oxidative modification. Autophagy. 2020;16(10):1838\u201350. https:\/\/doi.org\/10.1080\/15548627.2019.1709763.","journal-title":"Autophagy"},{"key":"3029_CR111","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.freeradbiomed.2018.11.020","volume":"130","author":"Z Li","year":"2019","unstructured":"Li Z, et al. The interaction of Atg4B and Bcl-2 plays an important role in Cd-induced crosstalk between apoptosis and autophagy through disassociation of Bcl-2-Beclin1 in A549 cells. Free Radic Biol Med. 2019;130:576\u201391. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.11.020.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3029_CR112","first-page":"31","volume":"13","author":"S Sudarsanam","year":"2010","unstructured":"Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 2010;13(1):31\u201340.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"7","key":"3029_CR113","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.febslet.2010.01.017","volume":"584","author":"CH Jung","year":"2010","unstructured":"Jung CH, et al. Mtor regulation of autophagy. FEBS Lett. 2010;584(7):1287\u201395. https:\/\/doi.org\/10.1016\/j.febslet.2010.01.017.","journal-title":"FEBS Lett"},{"key":"3029_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.625332","volume":"10","author":"R Liu","year":"2020","unstructured":"Liu R, et al. Molecular mechanisms of MYCN dysregulation in cancers. Front Oncol. 2020;10:625332. https:\/\/doi.org\/10.3389\/fonc.2020.625332.","journal-title":"Front Oncol"},{"key":"3029_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.624079","volume":"10","author":"J Otte","year":"2020","unstructured":"Otte J, et al. MYCN function in neuroblastoma development. Front Oncol. 2020;10:624079. https:\/\/doi.org\/10.3389\/fonc.2020.624079.","journal-title":"Front Oncol"},{"issue":"17\u201318","key":"3029_CR116","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1101\/gad.340133.120","volume":"34","author":"E Grunblatt","year":"2020","unstructured":"Grunblatt E, et al. MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. Genes Dev. 2020;34(17\u201318):1210\u201326. https:\/\/doi.org\/10.1101\/gad.340133.120.","journal-title":"Genes Dev"},{"key":"3029_CR117","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/cddiscovery.2016.82","volume":"2","author":"G Casinelli","year":"2016","unstructured":"Casinelli G, et al. N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics. Cell Death Discov. 2016;2:16082. https:\/\/doi.org\/10.1038\/cddiscovery.2016.82.","journal-title":"Cell Death Discov"},{"issue":"10","key":"3029_CR118","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/1878-0261.13507","volume":"17","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Cadherin-11 increases tumor cell proliferation and metastatic potential via Wnt pathway activation. Mol Oncol. 2023;17(10):2056\u201373. https:\/\/doi.org\/10.1002\/1878-0261.13507.","journal-title":"Mol Oncol"},{"key":"3029_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.782186","volume":"12","author":"BE Heinly","year":"2022","unstructured":"Heinly BE, Grant CN. Cell adhesion molecules in neuroblastoma: complex roles, therapeutic potential. Front Oncol. 2022;12:782186. https:\/\/doi.org\/10.3389\/fonc.2022.782186.","journal-title":"Front Oncol"},{"issue":"2","key":"3029_CR120","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ygyno.2017.08.010","volume":"147","author":"H Duan","year":"2017","unstructured":"Duan H, et al. TET1 inhibits EMT of ovarian cancer cells through activating Wnt\/\u03b2-catenin signaling inhibitors DKK1 and SFRP2. Gynecol Oncol. 2017;147(2):408\u201317. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.010.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3029_CR121","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbrc.2016.06.037","volume":"477","author":"XC Wu","year":"2016","unstructured":"Wu XC, et al. Down-regulation of transducin-like enhancer of split protein 4 in hepatocellular carcinoma promotes cell proliferation and epithelial-mesenchymal-transition. Biochem Biophys Res Commun. 2016;477(2):161\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2016.06.037.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"3029_CR122","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1159\/000494862","volume":"50","author":"X Zeng","year":"2018","unstructured":"Zeng X, et al. Secreted frizzled related protein 2 modulates epithelial-mesenchymal transition and stemness via Wnt\/\u03b2-catenin signaling in choriocarcinoma. Cell Physiol Biochem. 2018;50(5):1815\u201331. https:\/\/doi.org\/10.1159\/000494862.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3029_CR123","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62. https:\/\/doi.org\/10.1186\/s12935-020-01719-5.","journal-title":"Cancer Cell Int"},{"issue":"8","key":"3029_CR124","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/cas.14086","volume":"110","author":"H Yang","year":"2019","unstructured":"Yang H, et al. Extracellular ATP promotes breast cancer invasion and epithelial-mesenchymal transition via hypoxia-inducible factor 2\u03b1 signaling. Cancer Sci. 2019;110(8):2456\u201370. https:\/\/doi.org\/10.1111\/cas.14086.","journal-title":"Cancer Sci"},{"key":"3029_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154244","volume":"241","author":"S Khalilian","year":"2023","unstructured":"Khalilian S, et al. A review on the role of miR-210 in human disorders. Pathol Res Pract. 2023;241:154244. https:\/\/doi.org\/10.1016\/j.prp.2022.154244.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"3029_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16079","volume":"9","author":"G Cao","year":"2023","unstructured":"Cao G, et al. MiR-210 regulates lung adenocarcinoma by targeting HIF-1\u03b1. Heliyon. 2023;9(5):e16079. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16079.","journal-title":"Heliyon"},{"key":"3029_CR127","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7703159","author":"Z Xing","year":"2021","unstructured":"Xing Z, et al. Effect of MiR-210 on the chemosensitivity of breast cancer by regulating JAK-STAT signaling pathway. BioMed Res Int. 2021. https:\/\/doi.org\/10.1155\/2021\/7703159.","journal-title":"BioMed Res Int"},{"key":"3029_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.701488","volume":"11","author":"P Liu","year":"2021","unstructured":"Liu P, et al. Hypoxia-induced lncRNA-MIR210HG promotes cancer progression by inhibiting HIF-1\u03b1 degradation in ovarian cancer. Front Oncol. 2021;11:701488. https:\/\/doi.org\/10.3389\/fonc.2021.701488.","journal-title":"Front Oncol"},{"key":"3029_CR129","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.2147\/ott.S189468","volume":"12","author":"X Kang","year":"2019","unstructured":"Kang X, et al. LncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1. Onco Targets Ther. 2019;12:3779\u201390. https:\/\/doi.org\/10.2147\/ott.S189468.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"3029_CR130","doi-asserted-by":"publisher","first-page":"317","DOI":"10.21037\/atm-22-907","volume":"10","author":"C Ni","year":"2022","unstructured":"Ni C, et al. LINC00483 promotes proliferation and metastasis through the miR-19a-3p\/TBK1\/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). Ann Transl Med. 2022;10(6):317. https:\/\/doi.org\/10.21037\/atm-22-907.","journal-title":"Ann Transl Med"},{"issue":"1","key":"3029_CR131","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12935-022-02690-z","volume":"22","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, et al. A review on the role of LINC01133 in cancers. Cancer Cell Int. 2022;22(1):270. https:\/\/doi.org\/10.1186\/s12935-022-02690-z.","journal-title":"Cancer Cell Int"},{"key":"3029_CR132","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.12659\/msm.915926","volume":"25","author":"X Zhang","year":"2019","unstructured":"Zhang X, et al. Expression of circZNF609 is down-regulated in colorectal cancer tissue and promotes apoptosis in colorectal cancer cells by upregulating p53. Med Sci Monit. 2019;25:5977\u201385. https:\/\/doi.org\/10.12659\/msm.915926.","journal-title":"Med Sci Monit"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03029-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:27:17Z","timestamp":1762424837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03029-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":132,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3029"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03029-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable since original data from humans or animals have not been used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"470"}}